Global mRNA Therapeutics Market Size, Share, Trends & Growth Analysis Report 2026-2034

Description

The mRNA Therapeutics Market size is expected to reach USD 90.60 Billion in 2034 from USD 21.52 Billion (2025) growing at a CAGR of 17.32% during 2026-2034.

The global mRNA therapeutics market is experiencing rapid growth due to advancements in messenger RNA technology and its potential to treat a wide range of diseases. mRNA therapeutics work by delivering genetic instructions to cells, enabling them to produce specific proteins that can prevent or treat diseases. This innovative approach has gained significant attention in recent years due to its success in vaccine development.

Biotechnology companies and research institutions are exploring mRNA-based treatments for conditions such as cancer, genetic disorders, and infectious diseases. The flexibility of mRNA technology allows scientists to design therapies quickly and target specific disease mechanisms. Advances in delivery systems, such as lipid nanoparticles, are also improving the stability and effectiveness of mRNA therapeutics.

In the future, the market is expected to grow as clinical research continues to demonstrate the potential of mRNA-based treatments. Pharmaceutical companies are investing heavily in developing new therapeutic applications using this technology. As biotechnology innovation progresses, mRNA therapeutics are likely to become an important part of next-generation medical treatments.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Application

Infectious Diseases
Oncology
Rare Genetic Diseases
Respiratory Diseases
Others

By Type

Prophylactic
Therapeutic

By End-use

Hospitals & Clinics
Research Organizations
Others

COMPANIES PROFILED

Moderna Inc, BioNTech SE, CureVac NV, Arcturus Therapeutics Holdings Inc, Sanofi, GlaxoSmithKline plc, Argos Therapeutics Inc, Ethris GmbH, Pfizer Inc, AstraZeneca plc
We can customise the report as per your requirements.

Product Code: VMR112114584

Chapter 1. PREFACE

1.1. Market Segmentation & Scope
1.2. Market Definition
1.3. Information Procurement
- 1.3.1 Information Analysis
- 1.3.2 Market Formulation & Data Visualization
- 1.3.3 Data Validation & Publishing
1.4. Research Scope and Assumptions
- 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

2.1. Market Snapshot
2.2. Segmental Outlook
2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

3.1. Market Lineage Outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Value Chain Analysis
3.4. Regulatory Framework
- 3.4.1 Standards & Compliance
- 3.4.2 Regulatory Impact Analysis
3.5. Market Dynamics
- 3.5.1 Market Drivers
- 3.5.2 Market Restraints
- 3.5.3 Market Opportunities
- 3.5.4 Market Challenges
3.6. Porter's Five Forces Analysis
3.7. PESTLE Analysis

Chapter 4. GLOBAL MRNA THERAPEUTICS MARKET: BY APPLICATION 2022-2034 (USD MN)

4.1. Market Analysis, Insights and Forecast Application
4.2. Infectious Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
4.3. Oncology Estimates and Forecasts By Regions 2022-2034 (USD MN)
4.4. Rare Genetic Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
4.5. Respiratory Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
4.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL MRNA THERAPEUTICS MARKET: BY TYPE 2022-2034 (USD MN)

5.1. Market Analysis, Insights and Forecast Type
5.2. Prophylactic Estimates and Forecasts By Regions 2022-2034 (USD MN)
5.3. Therapeutic Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL MRNA THERAPEUTICS MARKET: BY END-USE 2022-2034 (USD MN)

6.1. Market Analysis, Insights and Forecast End-use
6.2. Hospitals & Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
6.3. Research Organizations Estimates and Forecasts By Regions 2022-2034 (USD MN)
6.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL MRNA THERAPEUTICS MARKET: BY REGION 2022-2034(USD MN)

7.1. Regional Outlook
7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 7.2.1 By Application
- 7.2.2 By Type
- 7.2.3 By End-use
- 7.2.4 United States
- 7.2.5 Canada
- 7.2.6 Mexico
7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 7.3.1 By Application
- 7.3.2 By Type
- 7.3.3 By End-use
- 7.3.4 United Kingdom
- 7.3.5 France
- 7.3.6 Germany
- 7.3.7 Italy
- 7.3.8 Russia
- 7.3.9 Rest Of Europe
7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 7.4.1 By Application
- 7.4.2 By Type
- 7.4.3 By End-use
- 7.4.4 India
- 7.4.5 Japan
- 7.4.6 South Korea
- 7.4.7 Australia
- 7.4.8 South East Asia
- 7.4.9 Rest Of Asia Pacific
7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 7.5.1 By Application
- 7.5.2 By Type
- 7.5.3 By End-use
- 7.5.4 Brazil
- 7.5.5 Argentina
- 7.5.6 Peru
- 7.5.7 Chile
- 7.5.8 South East Asia
- 7.5.9 Rest of Latin America
7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
- 7.6.1 By Application
- 7.6.2 By Type
- 7.6.3 By End-use
- 7.6.4 Saudi Arabia
- 7.6.5 UAE
- 7.6.6 Israel
- 7.6.7 South Africa
- 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

8.1. Recent Developments
8.2. Company Categorization
8.3. Supply Chain & Channel Partners (based on availability)
8.4. Market Share & Positioning Analysis (based on availability)
8.5. Vendor Landscape (based on availability)
8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL MRNA THERAPEUTICS INDUSTRY

9.1. Top Companies Market Share Analysis
9.2. Company Profiles
- 9.2.1 Moderna Inc
- 9.2.2 BioNTech SE
- 9.2.3 CureVac N.V
- 9.2.4 Arcturus Therapeutics Holdings Inc
- 9.2.5 Sanofi
- 9.2.6 GlaxoSmithKline Plc
- 9.2.7 Argos Therapeutics Inc
- 9.2.8 Ethris GmbH
- 9.2.9 Pfizer Inc
- 9.2.10 AstraZeneca Plc